Atorvastatin

Active ingredient description

Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Atorvastatin
C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AA HMG CoA reductase inhibitors
Discover more medicines within C10AA05

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Structured Product Labeling (SPL/PLR)
US
Summary of Product Characteristics (SPC)
UK

Medicines

Atorvastatin is the active ingredient of these drugs:

Drug
Countries

Lithuania

South Africa

Ecuador

South Africa

South Africa

Turkey

Cyprus Romania

Turkey

Ecuador

Italy

Romania

South Africa

Estonia Lithuania

South Africa

Brazil

Hong Kong

Singapore

Brazil

Turkey

Estonia

Singapore

Austria

Finland

Estonia Lithuania

Estonia Germany Hong Kong Italy Lithuania

Ecuador

Hong Kong

Brazil

Hong Kong

Austria

Singapore

Cyprus

Australia

Austria

Poland

Austria

Brazil Poland

Tunisia

Austria

Singapore

Poland

Poland

Hong Kong

Ecuador

Poland

Ecuador

Tunisia

Poland

Singapore

Ecuador

Turkey

Turkey

Singapore

Hong Kong

Poland

Austria

Hong Kong

Spain

Turkey

Hong Kong

Tunisia

South Africa

Turkey

Brazil

Turkey

Brazil

Poland

Cyprus

South Africa

Hong Kong Turkey

South Africa

Singapore

Ecuador

Ecuador

South Africa

Singapore

South Africa

Hong Kong

Italy

Turkey

Brazil

Cyprus Poland

Tunisia

Poland

Hong Kong

South Africa

Ecuador

Ecuador

Ecuador

Hong Kong

Turkey

Hong Kong

Hong Kong

Brazil

Hong Kong

South Africa

Finland Hong Kong

Brazil

Turkey

Australia Brazil Canada Cyprus Ecuador

Hong Kong

Hong Kong

Ecuador

South Africa

Hong Kong

Ecuador

Ecuador

South Africa

Turkey

Brazil

Estonia Lithuania

Australia New Zealand

Brazil

Italy

Lithuania

Poland

Italy

Finland

Hong Kong

Spain

Turkey

Ecuador

Italy

Austria Estonia Germany Lithuania Poland

Tunisia

Romania

Ecuador Poland

Hong Kong

France Tunisia

Turkey

Tunisia

Italy

Spain

Cyprus Estonia Lithuania Poland Romania

Italy

Poland Singapore

Lithuania

Italy

Australia

Hong Kong Singapore

Turkey

Brazil

Italy

Italy

Ecuador

Australia

Estonia Poland Singapore

South Africa

Hong Kong

Brazil Ecuador

Italy

South Africa

Hong Kong

Hong Kong

New Zealand Spain

Ecuador

Atorvastatin is also found within below combination drugs:

ACROVASTIN AMLO , ACROZETIM , AMALORIS , AMLATOR , AMLOSATIN , AMSTADIN , ANCILLEG , ASTUCOR , ATODIP , ATOPIR , ATORDAPIN , ATORIMIB , ATORMIBE , ATORVALAN COMP , ATOZET , ATROLIP PLUS , CADIVAST , CADUET , CODUWON , COLEATEZ , COLMIBE , DUPLECOR , EUVASCOR , EXTROTAN , EZEATO , EZETAST , EZETEC PLUS , EZEVAST , FIXLIP , LIPERCOSYL , LIPERTANCE , LIPOMEGA , LIPONORM PLUS , LIPTA , LIPTRUZET , MIZETAM , NONAZET , NORVASTOR , ORVATEZ , PARVAXOR , RASERVAS , RESELIP , TACERNOL , TIAZOMET A , TORVAZIN PLUS , TORZELIP , TRATEZ , TRINOMIA , TRIVERAM , TULIP COMBO , ZENTASTA , ZETOVAR

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₃₃H₃₅FN₂O₅
Molecular mass: 558.64 g/mol

3D molecular structure

3D representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 134523-00-5
DrugBank Drug: DB01076
KEGG Drug: D07474
PubChem Compound: 60823
RxNorm Ingredient: 83367
SNOMED-CT Concept: 373444002
Atorvastatin (substance)
UNII Identifier: A0JWA85V8F
ATORVASTATIN